ElectroCore Granted FDA Approval For Gammacore Sapphire Neurology Treatment
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K211856
ElectroCore Granted U.S. Patent Titled ‘Mobile phone using non-invasive nerve stimulation
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6425&f=G&l=50&d=PTXT&p=129&S1=20210824&OS=20210824&RS=20210824
electroCore Announces New Reseller Agreement With Red One Medical Devices, LLC.
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC. (Red One). The partnership will further expand availability of
ECOR: Impressive Growth: Invigorating Guidance
By John Vandermosten, CFA
NASDAQ:ECOR
READ THE FULL ECOR RESEARCH REPORT
electroCore Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $1.27M Miss $1.32M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 53.85 percent increase over losses of $(0.13) per share from the
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
ElectroCore Highlights Publication In PharmacoEconomics
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company (the Company), today announced the release of an article entitled "gammaCore for Cluster Headaches: A NICE Medical
ElectroCore Shares Move Higher; Co Granted U.S. Patent Titled ‘Mobile phone for stimulating the trigeminal nerve to treat disorders’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6467&f=G&l=50&d=PTXT&p=130&S1=20210720&OS=20210720&RS=20210720